Wells Fargo Upgrades RxSight Inc. (RXST) to Overweight

Wells Fargo analyst Lawrence Biegelsen upgraded RxSight Inc. (NASDAQ: RXST) from Equal Weight to Overweight with a price target of $42.00.

For an analyst ratings summary and ratings history on RxSight Inc. click here. For more ratings news on RxSight Inc. click here.

Shares of RxSight Inc. closed at $37.53 yesterday.

You May Also Be Interested In

• Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform
• RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement
• Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs